Servier

Xention, Servier collaborate for atrial fibrillation treatment

Wednesday, October 2, 2013 12:59 PM

Xention, a Cambridge-based biopharmaceutical company specializing in discovery and development of ion channel-modulating drugs for atrial fibrillation (AF), and Servier, an independent French pharmaceutical company, have entered  a multi-year agreement for  development and commercialization of XEN-D0103, a selective Kv1.5 modulator discovered and developed by Xention for the treatment of AF.

More... »

Servier makes offer for all shares of Egis Pharmaceuticals

Wednesday, September 25, 2013 12:31 PM

Servier Group has announced a voluntary public offer (to be made by its wholly-owned subsidiary Arts et Techniques du Progrès) to purchase all outstanding shares in its majority-owned subsidiary Egis Pharmaceuticals for $126 per share in cash.

More... »

Amgen, Servier complete product collaboration

Thursday, August 15, 2013 09:30 AM

Biotechnology company Amgen and privately-run French research-based pharmaceutical company Servier have announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement announced  July 8, completing the transaction.

More... »

Amgen, Servier announce product collaboration

Thursday, July 11, 2013 01:01 PM

Biotechnology company Amgen and privately-run French research-based pharmaceutical company Servier have entered a collaboration agreement leveraging each company's commitment to cardiovascular disease.

More... »

MacroGenics, Servier to develop three anti-cancer DART products

Friday, September 21, 2012 11:56 AM

MacroGenics, a Rockville, Md.-based privately held biotech that develops next generation antibody therapeutics, and Servier, a privately-held French pharmaceutical company, have entered into an option agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at three undisclosed tumor targets.

More... »

Academic-industry collaboration seeks new drugs, treatments for autism

Monday, March 19, 2012 02:41 PM

An international consortium of scientists led by Roche, King's College London and Autism Speaks is collaborating on one of the largest ever academic-industry research projects, to find new methods for the development of drugs for autism spectrum disorder (ASD), which affects 1% of children worldwide.

More... »

Hybrigenics, Servier ink license and research agreement

Tuesday, October 11, 2011 11:38 AM

Hybrigenics and Servier have signed a license and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases.

More... »

Takeda's Trevor Smith assumes role of CEO

Thursday, April 7, 2011 11:46 AM

Takeda Pharmaceutical’s Trevor Smith, currently vice president, International Strategy, will assume the role of chief executive officer of Takeda Pharmaceuticals Europe for oversight of pan-European sales and marketing.

More... »